Copyright © 2000 American Medical Association. All rights reserved. From: Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis Arch Intern Med. 2000;160(19):2998-3003. doi:10.1001/archinte.160.19.2998 Figure Legend: Twelve-month cumulative incidence (by survival analysis) of discontinuation due to gastrointestinal adverse events. Relative risk for rofecoxib vs nonsteroidal anti-inflammatory drugs (NSAIDs) is 0.70 (95% confidence interval, 0.52-0.94). Date of download: 10/14/2017 Copyright © 2000 American Medical Association. All rights reserved.

Copyright © 2000 American Medical Association. All rights reserved. From: Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis Arch Intern Med. 2000;160(19):2998-3003. doi:10.1001/archinte.160.19.2998 Figure Legend: Twelve-month cumulative incidence (by survival analysis) of dyspeptic-type gastrointestinal adverse events. Six- and 12-month relative risks for rofecoxib vs nonsteroidal anti-inflammatory drugs (NSAIDs) are 0.85 (95% confidence interval, 0.74-0.97) and 0.88 (95% confidence interval, 0.78-1.01), respectively. Dyspeptic-type gastrointestinal adverse events included acid reflux, dyspepsia, epigastric discomfort, heartburn, nausea, and vomiting. Date of download: 10/14/2017 Copyright © 2000 American Medical Association. All rights reserved.